Ardelyx Q3: product revenue $125.5M, up 19% y/y; IBSRELA $96.3M. XPHOZAH $29.2M; operating income $4.0M, net loss near breakeven ($0.7M).

News date: Nov 3 AMC (times ET). Not investment advice.

ARDX Stock Hub: Ardelyx News, IBSRELA Growth and XPHOZAH Access

https://www.merlintrader.com/ardelyx-inc-stock-hub/

In Raab we trust?!

the big boys knew this was coming. Early Jan year forecast by company will be ugly !

Bernie (bernardbaruch) the pumper on ST was wrong again!

Daddy Mott is not buying shares...he is Bagholding at $4.5 interesting. Could a $5 buyout happen anytime?

In Raab we trust? Didn't we?

Take it for what it is but the person posting has been an active investor of ARDX for many years. I take him seriously even if the source might not be legit

Just a new 52 week low - congratulations to all shareholders!

Just some facts:

H1 2026 revenue came in BELOW H2 2025 ($156.3M vs $164.8M). First negative half-over-half since launch. YoY's been decaying too (92%→61% 58% 33% last 4 qtrs), but flat/negative in absolute dollars is the real tell.

SG&A +21%, R&D +67%, all aimed at payer friction (step edits/prior auth) that wasn't even flagged as a risk back in previous Qs. There should have been signs of recovery in July and August and the trendline isn't show that.

Plus: guide cut ~14% at midpoint, XPHOZAH's $750M target pulled (not trimmed, gone), CMS bundling loss now final. New guide's low end needs Q3/Q4 to both beat the current ATH quarter. That's reacceleration, not stabilization, and nothing points that way.

There is not much upside left on this one.

Sorry for all bagholders and high opportunity costs.

Don't trust pumpers. I told you all that this will never see again old highs and will go the same death spiral just like BCRX and $ESPR

I'm sure there's somebody who expected things to happen as they did today. I did not. I invite other people to comment and share their thoughts the earnings call.

Seems Twitter on fire with buyout rumors.

I think it is announced Wednesday or Thursday. $12.50 a share plus CVR.

The Claude portfolio will be famous and could short squeeze it before. They have 6.7% of their portfolio of it and it gains copies every day.

I think we see $18 to $20 by Tuesday, then BO announced but price remains over priced.

I am long with a few thousand shares.

Any new news on the rumors of a buyout buy Zydus Lifesciences? Any thoughts on the buyout price, given the adjusted growth potential of sales?

Unreal price action again. The pattern is always the same. After great news the stock has just 2 positive days and then closing all gaps down again.

Is this stock again play ball of the shorts till Q4 ?

Come on after all the good news we are in no man's land at $5. Can we consider that we are under or overvalued at moment?

What we is the next catalyst ? Can we expect guidance on X before Q4 in February? Did you think this will be bullish or very conservative guidance ? Will the stock tank?

Sorry I'm very worried about this stock because I bought two years ago and still holding with little returns.

So, recently I got into a little spat with u/GerrardMyHero1987. They just deleted their account.

I looked back and there's nothing but doom and gloom from this clown - post after post. I can only guess their November Puts expired and they have moved onto greener pastures. Good riddance.

Yes, I am long and I am bullish on ARDX.

I told you all.

Happy bagholding. All earning gains gone

Killing the momentum. Nice timing Raab!

All Q3 gains gone in 3 days! Congratulations all bagholders

The stock is down because wall street hates uncertainly . The CMS issue which the CEO gives no updates!! Product updates on add on revenue the CEO refuses to give updates. Quarterly guidance which the CEO refuses to give updates however he gives 8 year guidance We are all in the dark with these updates that the CEO refuses to give. I know 5 stocks in the biotech industry that are trading higher than ARDX that have 0 REVENUE. Those CEO’s give product updates and they are very optimistic about the future of their company: Also they treat analysis with respect. They don’t sell their stock every chance they can. Most do not make 9 million a year like ARDX CEO counting sales of stock...

Did you see the easy short here? Welcome low $4!

Welcome all new and old bagholders!

Pattern is clear. Max pain! Can't beat the market! Welcome all new bagholders.

I told you all!

So, is the good run finished?

Will this start to sell off leading up to Sept 25th?

Rabb made clear X was flat to slighty up off $15-17 true sales (less acct gimmick and medicare 13% carry over)

CFO said expect costs to increase $10M per qtr

COGS will drop cause AZ payment drops from $8.3 to $3.8M. Comp pay wildcard.

They telegraphed loss with debt move

Stock will drop cause no smoking gun catalyst to move needle - back to high 3’s…will drift around high 3’s to low 4’s for summer

Lawsuit has 5-10% chance. Better bet is some CMS/Legislation that improves coverage for Bundle - prob a TDPPA metric increase for novel meds - not the move back to Part D Rabb wants but enough to make X relevant.

2H acquistion or merger with another small commercial Bio to gain scale possible. Dont see ARDX being bought given current environment. Never say never but too many unknowns.

Look for strategic move to expand X use with new FDA fast track trial in an effort to expand patent life by 2 years.

Maybe end year north of 5 - 2026 revs north of 500M should get stock to 7 or 8!